Information regarding Quviviq (daridorexant) in South Africa is limited. DrugPatentWatch.com does not currently list patents or exclusivity data for daridorexant specifically within South Africa [1].
When will Quviviq be available in South Africa?
The availability of Quviviq in South Africa is not yet established. Drug approval timelines and market entry vary significantly by country, and there is no publicly available information indicating when daridorexant might be submitted for or receive regulatory approval in South Africa.
What is Quviviq used for?
Quviviq is a dual orexin receptor antagonist (DORA) approved in the United States and the European Union for the treatment of insomnia [2]. It works by blocking the wake-promoting signaling of the neurotransmitters orexin A and orexin B, thereby reducing the drive to wakefulness and facilitating sleep [3].
How does Quviviq work?
Daridorexant's mechanism of action involves binding to both orexin-1 and orexin-2 receptors in the brain. Orexins are neuropeptides that play a crucial role in maintaining wakefulness. By blocking their activity, Quviviq dampens the signals that keep a person awake, allowing for the onset and maintenance of sleep [3].
What are the potential side effects of Quviviq?
Common side effects of Quviviq reported in clinical trials include somnolence (sleepiness) and headache [2]. Other potential side effects may include dizziness and fatigue. Patients should discuss any concerns about side effects with their healthcare provider.
Are there other treatments for insomnia available in South Africa?
Yes, a range of treatments for insomnia are available in South Africa, including prescription medications such as benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), and other orexin receptor antagonists. Non-pharmacological treatments, such as cognitive behavioral therapy for insomnia (CBT-I), are also recommended [4]. The specific availability of newer DORAs beyond Quviviq would depend on local regulatory approvals and market introductions.